• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Strata Critical Medical Inc.

    6/17/26 4:12:02 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary
    Get the next $SRTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Strata Critical Medical, Inc. ("Issuer")

    (Name of Issuer)


    Common Stock, $0.0001 par value per share (the "Common Stock")

    (Title of Class of Securities)




    092667104

    (CUSIP Number)
    06/11/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    Northern Right Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,398,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,398,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,398,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    PN, IA

    Comment for Type of Reporting Person:  Note to Rows 6 and 8: Northern Right Capital Management, L.P. may be deemed to beneficially own 1,046,392 shares of Common Stock (as defined herein) currently held by the Managed Accounts (as defined herein).


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    Northern Right Capital (QP), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,686,941.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,686,941.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,686,941.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    Northern Right Long Only Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,664,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,664,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,664,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    Northern Right Fund GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,664,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,664,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,664,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    BC Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,398,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,398,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,398,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP Number(s):
    092667104


    1Names of Reporting Persons

    Matthew A. Drapkin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,398,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,398,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,398,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Strata Critical Medical, Inc. ("Issuer")
    (b)Address of issuer's principal executive offices:

    666 Third Avenue, 25th Floor, New York, NY 10017
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this statement on Schedule 13G (collectively, the "Reporting Persons") are: * Northern Right Capital Management, L.P. ("NRCMLP"), * Northern Right Capital (QP), L.P. ("QP"), * Northern Right Long Only Master Fund LP ("NRLO"), * Northern Right Fund GP LLC ("NRLO GP"), * BC Advisors, LLC ("BCA"), and * Matthew A. Drapkin ("Mr. Drapkin").
    (b)Address or principal business office or, if none, residence:

    The principal business address for each of the Reporting Persons is 9 Old Kings Highway South, 4th Floor, Darien, Connecticut 06820.
    (c)Citizenship:

    NRCMLP and QP are Texas limited partnerships. NRLO is a Cayman Islands exempted limited partnership. NRLO GP and BCA are Delaware limited liability companies. Mr. Drapkin is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share (the "Common Stock")
    (e)CUSIP Number(s):

    092667104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 17, 2026, NRCMLP beneficially owned 4,398,235 shares of Common Stock. QP beneficially owns and has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) 1,686,941 shares of Common Stock (the "QP Shares"), which represent approximately 1.9% of the outstanding shares of Common Stock. NRLO beneficially owns and has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) 1,664,902 shares of Common Stock (the "LO Shares"), which represent approximately 1.9% of the outstanding shares of Common Stock. NRCMLP, in its capacity as general partner of QP, may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the QP Shares. NRCMLP, in its capacity as investment manager for NRLO, may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the LO Shares. NRCMLP, in its capacity as investment manager for certain separate managed accounts on behalf of investment advisory clients (the "Managed Accounts"), may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the 1,046,392 shares of the Common Stock held by the Managed Accounts, which shares represent, in the aggregate, approximately 1.2% of the outstanding shares of Common Stock. NRCMLP disclaims beneficial ownership of all of the shares of Common Stock held by each of QP, NRLO and the Managed Accounts, in each case except to the extent of its pecuniary interest therein. BCA, as general partner of NRCMLP, may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the shares of Common Stock beneficially owned (or deemed beneficially owned) by NRCMLP. BCA disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. NRLO GP, as general partner of NRLO, may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the LO Shares. NRLO GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. Mr. Drapkin, as managing member of BCA and NRLO GP, may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the shares of Common Stock beneficially owned (or deemed beneficially owned) by BCA and NRLO GP. Mr. Drapkin disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. As of the date hereof, no Reporting Person beneficially owns any shares of Common Stock other than those set forth in Item 4 of this Statement.
    (b)Percent of class:

    The following percentage is based on 86,526,570 Common Stock outstanding as of April 27th, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 6th, 2026. As of June 17, 2026, the Reporting Persons may be deemed to have beneficially owned approximately 5.1% of the outstanding Common Stock.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Northern Right Capital Management, L.P.
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin, Managing Member of BC Advisors, LLC, the general partner of Northern Right Capital Management, L.P.
    Date:06/17/2026
     
    Northern Right Capital (QP), L.P.
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin, Managing Member of BC Advisors, LLC, the GP of Northern Right Capital Management, L.P. the GP of Northern Right Capital (QP), L.P.
    Date:06/17/2026
     
    Northern Right Long Only Master Fund LP
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin, Managing Member of Northern Right Fund GP LLC, the gen. part. of Northern Right Long Only Master Fund LP
    Date:06/17/2026
     
    Northern Right Fund GP LLC
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin, Managing Member
    Date:06/17/2026
     
    BC Advisors LLC
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin, Managing Member
    Date:06/17/2026
     
    Matthew A. Drapkin
     
    Signature:/s/ Matthew A. Drapkin
    Name/Title:Matthew A. Drapkin
    Date:06/17/2026
    Exhibit Information

    Exhibit A - Joint Filing Agreement

    Get the next $SRTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTA

    DatePrice TargetRatingAnalyst
    3/25/2026$8.00Buy
    Craig Hallum
    3/25/2026$8.00Buy
    B. Riley Securities
    12/2/2025$8.00Buy
    Lake Street
    More analyst ratings

    $SRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-CEO and CFO Heyburn William A. bought $76,044 worth of shares (17,000 units at $4.47), increasing direct ownership by 1% to 1,403,436 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    12/10/25 4:15:25 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Director Lauck Andrew bought $21,825 worth of shares (5,000 units at $4.37), increasing direct ownership by 4% to 135,642 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    12/5/25 4:21:01 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Strata Critical Medical Inc.

    SCHEDULE 13G - Strata Critical Medical, Inc. (0001779128) (Subject)

    6/17/26 4:12:02 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

    6/3/26 4:25:12 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Strata Critical Medical Inc.

    25-NSE - Strata Critical Medical, Inc. (0001779128) (Subject)

    5/6/26 4:04:39 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Strata Critical Medical with a new price target

    Craig Hallum initiated coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

    3/25/26 8:36:47 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    B. Riley Securities initiated coverage on Strata Critical Medical with a new price target

    B. Riley Securities initiated coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

    3/25/26 8:35:45 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Lake Street resumed coverage on Strata Critical Medical with a new price target

    Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

    12/2/25 8:39:50 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Co-CEO and CFO Heyburn William A. covered exercise/tax liability with 31,671 shares, decreasing direct ownership by 2% to 1,548,997 units (SEC Form 4) to satisfy tax liability

    4/A - Strata Critical Medical, Inc. (0001779128) (Issuer)

    6/18/26 4:10:37 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Amendment: Co-CEO and General Counsel Tomkiel Melissa M. covered exercise/tax liability with 29,730 shares, decreasing direct ownership by 2% to 1,892,774 units (SEC Form 4) (for tax liability)

    4/A - Strata Critical Medical, Inc. (0001779128) (Issuer)

    6/18/26 4:10:11 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Amendment: Chief Accounting Officer Cohen Amir covered exercise/tax liability with 4,655 shares, decreasing direct ownership by 3% to 146,608 units (SEC Form 4) to satisfy withholding tax

    4/A - Strata Critical Medical, Inc. (0001779128) (Issuer)

    6/18/26 4:10:26 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Strata Acquires Heart and Lung Transplant National Recovery Program, Expanding National Organ Recovery Platform

    Network of experienced transplant surgeons in key markets will immediately become available to all Strata customersAdds significant scale to Transplant Clinical, Strata’s fastest growing business line, with a similar, rapid growth trajectory$21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata’s capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Heart and Lung Transplant National Recovery Program ("HLT-NRP"), a provider of transplant surgical recovery services in the United

    6/24/26 9:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Acquires Louisville Perfusion Services

    NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. ("LPS"), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. "The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States," said Lou Verdetto, CEO of Strata's Clinical Division. "More than just unlocking the ability to win new perfusion contracts in the region, LPS also expands the national footpr

    6/2/26 9:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Expiration of Warrants

    NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), announced that its warrants, both the Public Warrants (NASDAQ:SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026. About Strata Critical Medical, Inc. Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated "one call" solution for donor organ recovery. Strata's core services include

    5/7/26 5:05:00 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Leadership Updates

    Live Leadership Updates

    View All

    Strata Acquires Heart and Lung Transplant National Recovery Program, Expanding National Organ Recovery Platform

    Network of experienced transplant surgeons in key markets will immediately become available to all Strata customersAdds significant scale to Transplant Clinical, Strata’s fastest growing business line, with a similar, rapid growth trajectory$21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata’s capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Heart and Lung Transplant National Recovery Program ("HLT-NRP"), a provider of transplant surgical recovery services in the United

    6/24/26 9:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical, Inc. Appoints Will Cook to Board of Directors

    NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office

    12/3/25 5:00:00 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Financials

    Live finance-specific insights

    View All

    Strata Acquires Louisville Perfusion Services

    NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. ("LPS"), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. "The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States," said Lou Verdetto, CEO of Strata's Clinical Division. "More than just unlocking the ability to win new perfusion contracts in the region, LPS also expands the national footpr

    6/2/26 9:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces First Quarter 2026 Results

    Revenue increased 87.4% year-over-year to $67.4 million in Q1 2026Logistics revenue and gross profit grew 32.4% and 29.9% year-over-year, respectively, in Q1 2026, which represents Strata's organic growthClinical revenue and gross profit sequential growth of 12.7% and 29.2%, respectively in Q1 2026 versus Q4 2025 Q1 2026 net income from continuing operations of $2.4 millionAdjusted EBITDA(1) of $6.4 million in Q1 2026Completed bolt-on acquisition of Ohio Valley Perfusion AssociatesReiterating full year 2026 guidance NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced financial results for the first quar

    5/6/26 7:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Acquires Ohio Valley Perfusion Associates

    NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. "Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform," said Louis Verdetto, CEO of Strata's Clinical Services Division. "These programs align well with our existing operations and allow us to further leverage our team of highly trained perfusionists to support cardiac surgery programs whil

    4/30/26 4:05:00 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary